Zelira Therapeutics Limited Price Chart
Zelira Therapeutics Limited ZLD.XA Financial and Trading Overview
| Zelira Therapeutics Limited stock price | 0.48 AUD |
| Previous Close | 1.65 AUD |
| Open | 1.72 AUD |
| Bid | 1.53 AUD x N/A |
| Ask | 4.45 AUD x N/A |
| Day's Range | 1.65 - 1.72 AUD |
| 52 Week Range | 1.6 - 3.2 AUD |
| Volume | 3 AUD |
| Avg. Volume | 1.02K AUD |
| Market Cap | N/A |
| Beta (5Y Monthly) | 0.595402 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.505 AUD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
ZLD.XA Valuation Measures
| Enterprise Value | 17.4M AUD |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 0.49151024 |
| Enterprise Value/Revenue | 19.553 |
| Enterprise Value/EBITDA | -1.592 |
Trading Information
Zelira Therapeutics Limited Stock Price History
| Beta (5Y Monthly) | 0.595402 |
| 52-Week Change | -48.43% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 3.2 AUD |
| 52 Week Low | 1.6 AUD |
| 50-Day Moving Average | 1.99 AUD |
| 200-Day Moving Average | 1.99 AUD |
ZLD.XA Share Statistics
| Avg. Volume (3 month) | 1.02K AUD |
| Avg. Daily Volume (10-Days) | 1.02K AUD |
| Shares Outstanding | N/A |
| Float | 6.63M |
| Short Ratio | N/A |
| % Held by Insiders | 37.36% |
| % Held by Institutions | 0% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | N/A |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | June 30, 2022 |
| Most Recent Quarter (mrq) | December 31, 2022 |
| Next Fiscal Year End | June 30, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -1269.16% |
| Gross Margin | 23.72% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -18.36% |
| Return on Equity (ttm) | -28.71% |
Income Statement
| Revenue (ttm) | 889.87K AUD |
| Revenue Per Share (ttm) | 0.1 AUD |
| Quarterly Revenue Growth (yoy) | -89.40% |
| Gross Profit (ttm) | 601.57K AUD |
| EBITDA | -10928264 AUD |
| Net Income Avi to Common (ttm) | -9956218 AUD |
| Diluted EPS (ttm) | -1.505 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 133.79K AUD |
| Total Cash Per Share (mrq) | 0.01 AUD |
| Total Debt (mrq) | 494.19K AUD |
| Total Debt/Equity (mrq) | 1.53 AUD |
| Current Ratio (mrq) | 1.161 |
| Book Value Per Share (mrq) | 3.357 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -8406495 AUD |
| Levered Free Cash Flow (ttm) | -4236170 AUD |
Profile of Zelira Therapeutics Limited
| Country | Australia |
| State | WA |
| City | Perth |
| Address | 101 St George's Terrace |
| ZIP | 6000 |
| Phone | 61 8 6558 0886 |
| Website | https://www.zeliratx.com |
| Industry | |
| Sector(s) | |
| Full Time Employees | N/A |
Zelira Therapeutics Limited, a bio-pharmaceutical company, engages in the research, development, and commercialisation of cannabinoid-based medicines for the treatment of various medical conditions in Australia. It offers formulations under the HOPE brand in Pennsylvania and Louisiana, as well as develops Zenivol, a cannabinoid-based medicine for treatment of chronic insomnia. The company also provides OTC products, including SprinJene, an oral care product; and RAF FIVE, a dermatology product, as well as ITURA, an advanced relief cream formula that targets multi-symptoms, such as numbness and tingling, muscle cramps, insensitivities, and pain associated with Peripheral Artery Disease and diabetes. Zelira Therapeutics has strategic partnerships with Curtin University; the Telethon Kids Institute; the University of Western Australia; St. Vincent's Hospital; and the Children's Hospital of Philadelphia. The company was formerly known as Zelda Therapeutics Limited and changed its name to Zelira Therapeutics Limited in December 2019. Zelira Therapeutics Limited was incorporated in 2003 and is headquartered in Perth, Australia.
Q&A For Zelira Therapeutics Limited Stock
What is a current ZLD.XA stock price?
Zelira Therapeutics Limited ZLD.XA stock price today per share is 0.48 AUD.
How to purchase Zelira Therapeutics Limited stock?
You can buy ZLD.XA shares on the Cboe AU exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Zelira Therapeutics Limited?
The stock symbol or ticker of Zelira Therapeutics Limited is ZLD.XA.
How many shares does Zelira Therapeutics Limited have in circulation?
The max supply of Zelira Therapeutics Limited shares is 0.
What is Zelira Therapeutics Limited Price to Earnings Ratio (PE Ratio)?
Zelira Therapeutics Limited PE Ratio is now.
What was Zelira Therapeutics Limited earnings per share over the trailing 12 months (TTM)?
Zelira Therapeutics Limited EPS is -1.505 AUD over the trailing 12 months.